While Gearing Up To Supply Biosimilars To U.S. And EU Markets, Will Leading Chinese Biotech 3SBio Be M&A Target?
This article was originally published in PharmAsia News
Executive Summary
BEIJING - One of China's leading biopharmaceutical developers, 3SBio, reported solid earnings for the third quarter of 2010, which could help make the firm ripe for a takeover by an international player
You may also be interested in...
3SBio To Capitalize On Global Biologics Boom, SciClone Delays Key Financial Filing - Chinese Earnings Roundup (Part 2 of 2)
Year-end and Q4 earnings results for Chinese healthcare operators and drug stores are shaped by a challenging environment imposed by China's healthcare reform and increasing drug pricing pressure. In 2010, a rising tide of inflation also increased minimum wages and labor costs across the country and impacted companies' bottom lines. Many firms have resorted to business diversification, innovation and enriched pipelines to sustain a strong growth.
3SBio To Capitalize On Global Biologics Boom, SciClone Delays Key Financial Filing - Chinese Earnings Roundup (Part 2 of 2)
Year-end and Q4 earnings results for Chinese healthcare operators and drug stores are shaped by a challenging environment imposed by China's healthcare reform and increasing drug pricing pressure. In 2010, a rising tide of inflation also increased minimum wages and labor costs across the country and impacted companies' bottom lines. Many firms have resorted to business diversification, innovation and enriched pipelines to sustain a strong growth.
Innovation To Drive Long-Term Survival In China Pharma Market - But What Kind Of Innovation?
BEIJING - For Big Pharma and domestic players competing in China's market, innovation is essential for long-term survival, even as pricing strategies might help grab market share over the shorter term, according to a prominent analyst who monitors China's healthcare sector